Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer

References

• Shen M, Pan H, Chen Y, Xu YH, Yang W, Wu Z. A review of current progress in triple-negative breast cancer therapy. Open Med. 2020;15(1):1143–1149. doi:10.1515/med-2020-0138
   Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721–1728. doi:10.1002/cncr.22618
   PubMed Web of Science ®Google Scholar
• Ghosh M, Saha S, Bettke J, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39(4):494–508 e495. doi:10.1016/j.ccell.2021.01.003
   PubMed Web of Science ®Google Scholar
• Wellenstein MD, de Visser KE. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity. 2018;48(3):399–416. doi:10.1016/j.immuni.2018.03.004
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Goncalves A, Rugo HS, et al. Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the Phase III EMBRACA trial. Oncologist. 2020;25(3):e439–e450. doi:10.1634/theoncologist.2019-0493
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32(2):240–249. doi:10.1016/j.annonc.2020.11.009
   PubMed Web of Science ®Google Scholar
• Hu H, Zhu J, Zhong Y, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. Ann Transl Med. 2021;9(5):410. doi:10.21037/atm-21-698
   PubMed Web of Science ®Google Scholar
• Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31(2):178–186. doi:10.1038/s41422-020-0375-9
   PubMed Web of Science ®Google Scholar
• Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491–1505. doi:10.1016/j.annonc.2020.07.014
   PubMed Web of Science ®Google Scholar
• Park AY, Han MR, Park KH, et al. Radiogenomic analysis of breast cancer by using B-mode and vascular US and RNA sequencing. Radiology. 2020;295(1):24–34. doi:10.1148/radiol.2020191368
   PubMed Web of Science ®Google Scholar
• Guo Y, Hu Y, Qiao M, et al. Radiomics analysis on ultrasound for prediction of biologic behavior in breast invasive ductal carcinoma. Clin Breast Cancer. 2018;18(3):e335–e344. doi:10.1016/j.clbc.2017.08.002
   PubMed Web of Science ®Google Scholar
• Xiong L, Chen H, Tang X, et al. Ultrasound-based radiomics analysis for predicting disease-free survival of invasive breast cancer. Front Oncol. 2021;11:621993. doi:10.3389/fonc.2021.621993
   PubMedGoogle Scholar
• Jiang M, Li CL, Luo XM, et al. Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer. Eur J Cancer. 2021;147:95–105. doi:10.1016/j.ejca.2021.01.028
   PubMed Web of Science ®Google Scholar
• Guo R, Lu G, Qin B, Fei B. Ultrasound imaging technologies for breast cancer detection and management: a review. Ultrasound Med Biol. 2018;44(1):37–70. doi:10.1016/j.ultrasmedbio.2017.09.012
   PubMed Web of Science ®Google Scholar
• Chen Q, Xia J, Zhang J. Identify the triple-negative and non-triple-negative breast cancer by using texture features of medical ultrasonic image: a STROBE-compliant study. Medicine. 2021;100(22):e25878. doi:10.1097/MD.0000000000025878
   PubMed Web of Science ®Google Scholar
• Wu T, Sultan LR, Tian J, Cary TW, Sehgal CM. Machine learning for diagnostic ultrasound of triple-negative breast cancer. Breast Cancer Res Treat. 2019;173(2):365–373. doi:10.1007/s10549-018-4984-7
   PubMed Web of Science ®Google Scholar
• Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol. 2010;20(5):1111–1117. doi:10.1007/s00330-009-1656-3
   PubMed Web of Science ®Google Scholar
• Nardone V, Reginelli A, Grassi R, et al. Delta radiomics: a systematic review. Radiol Med. 2021;126(12):1571–1583. doi:10.1007/s11547-021-01436-7
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li H, Guo W, et al. Deciphering genomic underpinnings of quantitative MRI-based radiomic phenotypes of invasive breast carcinoma. Sci Rep. 2015;5:17787. doi:10.1038/srep17787
   PubMed Web of Science ®Google Scholar
• Rios Velazquez E, Parmar C, Liu Y, et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res. 2017;77(14):3922–3930. doi:10.1158/0008-5472.CAN-17-0122
   PubMed Web of Science ®Google Scholar
• Huang Y, Qiang Y, Jian L, et al. Ultrasonic features and molecular subtype predict somatic mutations in TP53 and PIK3CA genes in breast cancer. Acad Radiol. 2022;29(12):e261–e270. doi:10.1016/j.acra.2022.02.021
   PubMed Web of Science ®Google Scholar
• Ronneberger OFP, Brox T. U-net: convolutional networks for biomedical image segmentation. International Conference on Medical image computing and computer-assisted intervention Springer, Cham; 2015:234–241.
   Google Scholar
• van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):e104–e107. doi:10.1158/0008-5472.CAN-17-0339
   PubMed Web of Science ®Google Scholar
• Lang GT, Jiang YZ, Shi JX, et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nat Commun. 2020;11(1):5679. doi:10.1038/s41467-020-19342-3
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412
   PubMed Web of Science ®Google Scholar
• Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427–438 e426. doi:10.1016/j.ccell.2018.08.008
   PubMed Web of Science ®Google Scholar
• Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428–440 e425. doi:10.1016/j.ccell.2019.02.001
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu F, Zhang H, et al. Diagnostic value of radiomics analysis in contrast-enhanced spectral mammography for identifying triple-negative breast cancer. Front Oncol. 2021;11:773196. doi:10.3389/fonc.2021.773196
   PubMed Web of Science ®Google Scholar
• Ye H, Hang J, Zhang M, et al. Automatic identification of triple negative breast cancer in ultrasonography using a deep convolutional neural network. Sci Rep. 2021;11(1):20474. doi:10.1038/s41598-021-00018-x
   PubMed Web of Science ®Google Scholar
• Zhang HX, Sun ZQ, Cheng YG, Mao GQ. A pilot study of radiomics technology based on X-ray mammography in patients with triple-negative breast cancer. J Xray Sci Technol. 2019;27(3):485–492. doi:10.3233/XST-180488
   PubMed Web of Science ®Google Scholar
• Youk JH, Son EJ, Chung J, Kim JA, Kim EK. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Eur Radiol. 2012;22(8):1724–1734. doi:10.1007/s00330-012-2425-2
   PubMed Web of Science ®Google Scholar
• Kojima Y, Tsunoda H. Mammography and ultrasound features of triple-negative breast cancer. Breast Cancer. 2011;18(3):146–151. doi:10.1007/s12282-010-0223-8
   PubMed Web of Science ®Google Scholar
• Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008;111(3):405–410. doi:10.1007/s10549-007-9810-6
   PubMed Web of Science ®Google Scholar
• Gao B, Zhang H, Zhang SD, et al. Mammographic and clinicopathological features of triple-negative breast cancer. Br J Radiol. 2014;87(1039):20130496. doi:10.1259/bjr.20130496
   PubMed Web of Science ®Google Scholar
• Zheng FY, Lu Q, Huang BJ, et al. Imaging features of automated breast volume scanner: correlation with molecular subtypes of breast cancer. Eur J Radiol. 2017;86:267–275. doi:10.1016/j.ejrad.2016.11.032
   PubMed Web of Science ®Google Scholar
• Matsuda M, Tsuda T, Ebihara R, et al. Triple-negative breast cancer on contrast-enhanced MRI and synthetic MRI: a comparison with non-triple-negative breast carcinoma. Eur J Radiol. 2021;142:109838. doi:10.1016/j.ejrad.2021.109838
   PubMed Web of Science ®Google Scholar
• Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol. 2010;194(4):1160–1166. doi:10.2214/AJR.09.2355
   PubMed Web of Science ®Google Scholar
• Ko ES, Kim JH, Lim Y, Han BK, Cho EY, Nam SJ. Assessment of invasive breast cancer heterogeneity using whole-tumor magnetic resonance imaging texture analysis: correlations with detailed pathological findings. Medicine. 2016;95(3):e2453. doi:10.1097/MD.0000000000002453
   PubMed Web of Science ®Google Scholar
• Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol. 2012;67(2):157–164. doi:10.1016/j.crad.2011.08.012
   PubMed Web of Science ®Google Scholar
• Zhang H, Sui X, Zhou S, Hu L, Huang X. Correlation of conventional ultrasound characteristics of breast tumors with axillary lymph node metastasis and Ki-67 expression in patients with breast cancer. J Ultrasound Med. 2019;38(7):1833–1840. doi:10.1002/jum.14879
   PubMed Web of Science ®Google Scholar
• Khairalseed M, Javed K, Jashkaran G, Kim JW, Parker KJ, Hoyt K. Monitoring early breast cancer response to neoadjuvant therapy using H-scan ultrasound imaging: preliminary preclinical results. J Ultrasound Med. 2019;38(5):1259–1268. doi:10.1002/jum.14806
   PubMed Web of Science ®Google Scholar
• Moon WK, Chen HH, Shin SU, Han W, Chang RF. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI. Magn Reson Imaging. 2019;63:60–69. doi:10.1016/j.mri.2019.08.026
   PubMed Web of Science ®Google Scholar
• Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ. Association of BRCA mutation types, imaging features, and pathologic findings in patients with breast cancer with BRCA1 and BRCA2 mutations. AJR Am J Roentgenol. 2017;209(4):920–928. doi:10.2214/AJR.16.16957
   PubMed Web of Science ®Google Scholar
• Olivier M, Taniere P. Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Curr Opin Oncol. 2011;23(1):88–92. doi:10.1097/CCO.0b013e3283412dfa
   PubMed Web of Science ®Google Scholar
• Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7(4):a016600. doi:10.1101/cshperspect.a016600
   PubMed Web of Science ®Google Scholar
• Pop LA, Cojocneanu-Petric RM, Pileczki V, et al. Genetic alterations in sporadic triple negative breast cancer. Breast. 2018;38:30–38. doi:10.1016/j.breast.2017.11.006
   PubMed Web of Science ®Google Scholar
• Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 2018;18(5):e841–e850. doi:10.1016/j.clbc.2018.07.023
   PubMed Web of Science ®Google Scholar
• Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38(36):4274–4282. doi:10.1200/JCO.20.02151
   PubMed Web of Science ®Google Scholar
• Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM. PARP inhibitors in the treatment of triple-negative breast cancer. Clin Pharmacokinet. 2018;57(4):427–437. doi:10.1007/s40262-017-0587-4
   PubMed Web of Science ®Google Scholar
• Chew NJ, Nguyen EV, Su SP, et al. FGFR3 signaling and function in triple negative breast cancer. Cell Commun Signal. 2020;18(1):13. doi:10.1186/s12964-019-0486-4
   PubMed Web of Science ®Google Scholar
• Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30(7):1051–1060. doi:10.1093/annonc/mdz133
   PubMed Web of Science ®Google Scholar
• Di Cosimo S, Appierto V, Silvestri M, et al. Targeted-gene sequencing to catch triple negative breast cancer heterogeneity before and after neoadjuvant chemotherapy. Cancers. 2019;11(11):1753. doi:10.3390/cancers11111753
   PubMed Web of Science ®Google Scholar